1. United States Drug Enforcement Administration. DEA reduces amount of opioid controlled substances to be manufactured in 2017; October 4, 2016. Available from: https://www.dea.gov/press-releases/2016/10/04/dea-reduces-amount-opioid-controlled-substances-be-manufactured-2017. Accessed September 15, 2020.

2. United States Drug Enforcement Administration. DEA proposes reduction to amount of controlled substances to be manufactured in 2018; August 4, 2017. Available from: https://www.dea.gov/press-releases/2017/08/04/dea-proposes-reduction-amount-controlled-substances-be-manufactured-2018. Accessed September 15, 2020.

3. United States Drug Enforcement Administration. Justice Department, DEA propose significant opioid manufacturing reduction in 2019; August 16, 2019. Available from: https://www.dea.gov/press-releases/2018/08/16/justice-department-dea-propose-significant-opioid-manufacturing-reduction. Accessed September 15, 2020.

4. United States Drug Enforcement Administration. DEA proposes to reduce the amount of five opioids manufactured in 2020, marijuana quota for research increases by almost a third; September 11, 2019. Available from: https://www.dea.gov/press-releases/2019/09/11/dea-proposes-reduce-amount-five-opioids-manufactured-2020-marijuana-quota. Accessed September 28, 2020.

5. United States Drug Enforcement Administration. Adjustments to aggregate production quotas for certain schedule II controlled substances and assessment of annual needs for the list i chemicals ephedrine and pseudoephedrine for 2020, in response to the coronavirus disease 2019 public health emergency; April 10, 2020. Available from: https://www.deadiversion.usdoj.gov/fed_regs/quotas/2020/fr0410.htm. Accessed September 28, 2020.